Daiichi Sankyo
Clinical trials sponsored by Daiichi Sankyo, explained in plain language.
A global pharmaceutical company developing medicines, notably in oncology.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for aggressive lung cancer: combo therapy enters human trials Results expected Sep 2026 (estimated)
- New hope for advanced tumors? first human trial of DS-3939a begins Results expected Oct 2026 (estimated)
- Liver impairment study tests cancer drug safety Results expected Oct 2026 (estimated)
- Can a new drug target Hard-to-Treat kidney and ovarian cancers? Results expected Dec 2026 (estimated)
- Can Real-World data confirm T-DXd's promise in HER2-Mutant lung cancer? Results expected Feb 2027 (estimated)
-
Triple-Drug cocktail aims to reverse early heart disease
Disease control Not yet recruitingThis Phase 3 trial will test whether a combination of three cholesterol-lowering drugs—bempedoic acid, ezetimibe, and a high-intensity statin—can reduce and stabilize plaque buildup in the coronary arteries. The study enrolls 103 adults with coronary atherosclerosis who have neve…
Phase 3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a targeted drug duo hold off ovarian cancer's return?
Disease control Not yet recruitingThis trial tests whether raludotatug deruxtecan, given alone or with bevacizumab, can delay cancer growth better than standard care in people with platinum-sensitive ovarian, primary peritoneal, or fallopian tube cancer that has returned after first treatment. About 600 adults as…
Phase 3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis trial is testing an experimental drug called DS-3939a in adults with advanced solid tumors, including a type of lung cancer. The study has two parts: the first checks safety and the best dose, and the second looks at whether the drug, alone or with other cancer treatments, c…
Phase 1/2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug sequence aims to outsmart advanced breast cancer
Disease control Not yet recruitingThis trial tests a planned sequence of treatments for people with advanced or metastatic HER2-positive and hormone receptor-positive breast cancer. Participants first receive T-DXd (Enhertu) plus pertuzumab, then switch to a maintenance combination of palbociclib, endocrine thera…
Phase 3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Double-Barreled drug attack targets Hard-to-Treat breast cancer
Disease control Not yet recruitingThis trial is studying a combination of two targeted drugs, patritumab deruxtecan and trastuzumab deruxtecan, for people with a specific type of advanced breast cancer that is hormone receptor positive and has low or ultra-low levels of a protein called HER2. The study aims to fi…
Phase 1/2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC